Highlights Johnson & Johnson London S.E.

Equities

0R34

US4781601046

Market Closed - London S.E. Other stock markets 11:35:05 2024-07-04 am EDT			5-day change	1st Jan Change
146.5 ^USD	+0.96%		-1.21%	+352.72%

Jul. 03	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
Jul. 03	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

J&J: promising results in multiple myeloma	Jul. 02	CF
Johnson & Johnson Says Interim Analysis of Blood Cancer Therapy Study Show Promise	Jul. 02	MT
Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI	Jul. 02	CI
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	Jun. 28	MT
J&J Unit's Rybrevant Combo Gets EU Approval	Jun. 28	MT
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	Jun. 28	CI
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	Jun. 28	MT
Dealmakers optimistic on global M&A prospects despite sluggish growth	Jun. 28	RE
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	Jun. 27	RE
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	Jun. 24	RE
J&J: 50M pupils helped through 'Sight for Kids' program	Jun. 24	CF
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	Jun. 21	MT
Johnson & Johnson: acquisition of Proteologix completed	Jun. 21	CF
Johnson & Johnson Completes Acquisition of Proteologix	Jun. 21	MT
Johnson & Johnson Completes Acquisition of Proteologix	Jun. 21	MT
Johnson & Johnson Completes Acquisition of Proteologix	Jun. 21	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	Jun. 20	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	Jun. 20	MT
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	Jun. 20	CI
J&J: launches open, secure digital ecosystem	Jun. 20	CF

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST